Natera

YTD

ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).

CEO

Stephen Leonard Chapman

CEOStephen Leonard Chapman

Employees

6,140

Employees6,140

Headquarters

Austin, Texas

HeadquartersAustin, Texas

Founded

2003

Founded2003

Employees

6,140

Employees6,140

NTRA Key Statistics

Market cap

39.89B

Market cap39.89B

Price-Earnings ratio

-167.67

Price-Earnings ratio-167.67

Dividend yield

—

Dividend yield—

Average volume

1.06M

Average volume1.06M

High today

$279.97

High today$279.97

Low today

$275.19

Low today$275.19

Open price

$275.19

Open price$275.19

Volume

299.31K

Volume299.31K

52 Week high

$288.04

52 Week high$288.04

52 Week low

$134.85

52 Week low$134.85

Stock Snapshot

With a market cap of 39.89B, Natera(NTRA) trades at $275.85. The stock has a price-to-earnings ratio of -167.67.

On 2026-08-05, Natera(NTRA) stock moved within a range of $275.19 to $279.97. With shares now at $275.85, the stock is trading +0.2% above its intraday low and -1.5% below the session's peak.

Trading activity shows a volume of 299.31K, compared to an average daily volume of 1.06M.

Over the past 52 weeks, Natera(NTRA) stock has traded between a high of $288.04 and a low of $134.85.

NTRA News

Nasdaq 4h

Natera Files For Japan PMDA Approval Of Signatera Test In Bladder Cancer

(RTTNews) - Natera, Inc. (NTRA), a genetic testing company said on Wednesday that it has filed for approval in Japan to use its Signatera test as a companion di...

TipRanks 5h

Natera submits Signatera test to Japan’s PMDA for approval as CDx

Natera (NTRA) announced that it has submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency for approval of the Signatera test in muscle-...

The Motley Fool 1d

Stanley Druckenmiller Put 18% of His $3.4 Billion Portfolio in This One Stock. Is Natera a Buy?

It can pay to track what the big investors on Wall Street are trading in quarterly 13-F filings. This quarter, legendary hedge fund manager Stanley Druckenmille...

Analyst ratings

88%

of 24 ratings

Buy

87.5%

Hold

12.5%

Sell

More NTRA News

Simply Wall St 3d

Natera Stock Trades At A Premium To Sales After A 425% Return

Natera stock has delivered a very large 424.8% return over the past three years, yet the company currently screens as expensive on several valuation checks. Wit...

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.

Flowserve

iShares MSCI Emerging Mar…

CSX

Alcoa

Linde plc

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.